WHERE WE ARE
The market clearly does not like that last PR announcing we'll be doing our own testing on the dry eye drop application. Many might have been hoping that the positive results from the CRO testing would result in discussions with Big Pharma for licensing deals. We don't know anything at this point about whether any discussions like that have even occurred. This decision to test it ourselves now moves the time frame out many months, and possible much longer, as getting through FDA approvals is a lengthy and often unpredictable process--especially now in this new age of the Corona Virus.
Much more puzzling to me is the absence of ANY WORD on the status of Dr. Evans' Macular Degeneration studies at the U. of British Columbia. This animal trials ended in November and one would think that he'd have a journal article ready to go for submission very quickly after that. What's going on with all that? Has an article even been submitted, and if not, why?
The MacD is possibly the only short term price propeller we now have, since publication in a major vision journal would generate some world-wide interest by Big Pharma.
Additionally, why is the Dr. Schapiro diabetes study in Alberta a 1B trial rather than a full-fledged Phase 2 Trial? Is it because of the small number of patients enrolled in the first phase? Time wise, it doesn't seem to me that the diabetes study will lead to any short term price improvements.
So, we may now be in a much longer waiting game for share price increases than originally hoped for.
Comments welcome.
